Yes. At Astra Health, code NEWSTART takes $100 off the 12-month compounded tirzepatide plan: $109/month instead of $118 ($1,316 billed once instead of $1,416). Use the link to apply it automatically or enter it at checkout.
Updated · prices checked against manufacturer pages
Use code NEWSTART for $100 off Astra's compounded tirzepatide: $109 a month instead of $118 on the 12-month plan — $1,316 billed once instead of $1,4164. Open the link below and the code is already applied, or type it during checkout.
Brand-name tirzepatide (Zepbound®) self-pay through LillyDirect is $299 to $449 a month depending on dose, or as little as $25 with commercial insurance that covers it3. They are different products — the comparison is below.
Code
Compounded tirzepatide: code NEWSTART — $100 off. $109/mo instead of $118/mo on the 12-month plan ($1,316 billed once instead of $1,416).
Apply NEWSTART automatically →Click a button to start with the code already applied, or type the code during checkout. NEWSTART applies to the 12-month compounded tirzepatide plan. Plans are billed upfront, renew automatically and can be cancelled any time. A licensed physician decides whether treatment is appropriate; a visit does not guarantee a prescription. Compounded medications are not FDA-approved. Subscription terms · Refund policy. Last verified 2026-10-01.
Lowest published monthly price for each option. Compounded and brand-name medications are different products; compounded medications are not FDA-approved.
| Astra compounded tirzepatide | Zepbound® (brand) | |
|---|---|---|
| Monthly cost (self-pay) | $109 with NEWSTART ($118 regular), 12-month plan | $299–$449 by dose3 |
| FDA approval | Not FDA-approved (compounded) | FDA-approved |
| Doctor visit | Included | Separate — you need your own prescriber |
| Price by dose | Same price at every dose | Rises from $299 to $449 as the dose goes up3 |
| With commercial insurance | Not billed to insurance | As little as $25 if covered (max $100/month, $1,300/year)3 |
If your insurance covers Zepbound®, Lilly's savings card is likely the cheapest route. If you are paying cash, compare the totals above. Astra also offers brand-name Zepbound® where clinically appropriate.
Yes. At Astra Health, code NEWSTART takes $100 off the 12-month compounded tirzepatide plan: $109/month instead of $118 ($1,316 billed once instead of $1,416). Use the link to apply it automatically or enter it at checkout.
With commercial insurance that covers Zepbound®, Lilly's savings card lets eligible patients pay as little as $25 (government beneficiaries excluded). Paying cash, Astra's compounded tirzepatide is $109/month with code NEWSTART on the 12-month plan, while Zepbound® self-pay through LillyDirect is $299–$449/month depending on dose.
At Astra, compounded tirzepatide is the same price at every dose and physician-directed dose increases are included. Zepbound® self-pay through LillyDirect is $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5–15 mg per month.
No. Both contain tirzepatide, but compounded tirzepatide is prepared by a licensed compounding pharmacy and is not FDA-approved, while Zepbound® is the FDA-approved brand-name product. A licensed physician decides which, if either, is appropriate for you.
Yes. With commercial insurance that covers Zepbound®, Lilly's savings card lets eligible patients pay as little as $25 for a 1-, 2- or 3-month fill (maximum savings $100 per month and $1,300 per calendar year; government beneficiaries excluded). Without coverage, LillyDirect self-pay is $299 (2.5 mg), $399 (5 mg) or $449 (7.5–15 mg) a month, with a refill required within 45 days to keep the price.
NEWSTART applies to the 12-month compounded tirzepatide plan, billed upfront. Plans renew automatically and can be cancelled any time.
Educational information, not medical advice. NEWSTART applies to the 12-month compounded tirzepatide plan. Plans are billed upfront, renew automatically and can be cancelled any time. A licensed physician decides whether treatment is appropriate; a visit does not guarantee a prescription. Compounded medications are not FDA-approved. Wegovy® is a registered trademark of Novo Nordisk A/S and Zepbound® of Eli Lilly and Company; Astra Health is not affiliated with either.